Table 2.
Baseline TQOL as Predictors of In-Trial Stroke
| All TQOL | TQoL Quartile 1 (Lowest) | TQoL Quartile 2 | TQoL Quartile 3 | TQoL Quartile 4 (Highest) | |
|---|---|---|---|---|---|
| HR for stroke per 0.1 unit (95% CI) | |||||
| Unadjusted | 0.90 (0.87 – 0.93) | --- | --- | --- | --- |
| Adjusted* | 0.93 (0.89 – 0.98) | --- | --- | --- | --- |
| HR by quartile*, unadjusted | --- | 1.36 (1.18 – 1.58) | 1.16 (1.00 – 1.35) | 0.96 (0.82 – 1.12) | 1.00 (ref) |
| HR by quartile, adjusted** | --- | 1.20 (1.00 – 1.44) | 1.02 (0.85 – 1.24) | 0.97 (0.80 – 1.17) | 1.00 (ref) |
| 5-year cumulative stroke rates by quartile | 0.048 (0.045 – 0.050) | 0.060 (0.053 – 0.064) | 0.050 (0.044 – 0.055) | 0.041 (0.037 – 0.046) | 0.042 (0.038 – 0.048) |
| Number of events by quartile (% of events) | 1312 | 418 (0.31) | 333 (0.25) | 297 (0.23) | 264 (0.20) |
Abbreviations: TQOL=transformed quality of life; HR=hazard ratio
*
Range of VAS within each quartile of Qol - Highest Quartile >−.85, 3rd Quartile 0.75–0.85, 2nd Quartile 0.65–0.75, Lowest Quartile <0.65.
**
Adjusted for antihypertensive treatment group, age, gender, race, prior MI or stroke, diabetes, history of CHD, smoking status, and baseline SBP, DBP, atrial fibrillation, total cholesterol, LDL, HDL, triglycerides, and aspirin use.